BioNTech (NASDAQ:BNTX) Stock Rating Upgraded by Evercore ISI

Evercore ISI upgraded shares of BioNTech (NASDAQ:BNTX) from an in-line rating to an outperform rating in a research report released on Tuesday, Marketbeat.com reports. Evercore ISI currently has $125.00 price target on the stock, up from their prior price target of $110.00.

BNTX has been the topic of several other research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 target price on shares of BioNTech in a research report on Thursday, November 14th. Bank of America increased their target price on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. UBS Group increased their target price on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research report on Wednesday, September 18th. TD Cowen dropped their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a research report on Monday. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus price target of $138.79.

BioNTech Trading Up 5.9 %

BNTX opened at $108.20 on Tuesday. The stock’s fifty day moving average is $113.80 and its two-hundred day moving average is $97.56. The company has a market capitalization of $25.94 billion, a P/E ratio of -51.52 and a beta of 0.26. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.73 EPS. Analysts forecast that BioNTech will post -3.68 earnings per share for the current year.

Institutional Trading of BioNTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Candriam S.C.A. raised its stake in shares of BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after buying an additional 418,695 shares during the last quarter. Baillie Gifford & Co. increased its stake in shares of BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after purchasing an additional 31,773 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of BioNTech by 63.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock valued at $2,249,000 after purchasing an additional 7,340 shares in the last quarter. Discovery Capital Management LLC CT purchased a new position in shares of BioNTech in the 2nd quarter valued at about $2,467,000. Finally, Deerfield Management Company L.P. Series C increased its stake in shares of BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock valued at $47,734,000 after purchasing an additional 24,426 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.